Esposito Pamela 4

What Happened

• Pamela Esposito, a director of Kymera Therapeutics (KYMR), exercised options to acquire 2,500 shares at $49.10 each (total cost $122,750) on Feb 20, 2026. On the same date she sold a total of 2,500 shares in open-market transactions (1,900 shares at a weighted avg $87.06 and 600 shares at a weighted avg $88.10), producing aggregate proceeds of about $218,270.
• The filing also lists a separate derivative entry showing 2,500 shares disposed at $0.00; the report does not provide further detail on that $0.00 line. Footnote F4 states the shares underlying the option were fully vested and exercisable.

Key Details

• Date of transactions: 2026-02-20.
• Sales: 1,900 shares sold at weighted average $87.06 (prices ranged $86.52–$87.49 per F2); 600 shares sold at weighted average $88.10 (prices ranged $87.58–$88.40 per F3). Total sales proceeds ≈ $218,270.
• Exercise: 2,500 shares acquired at $49.10; total cash paid ≈ $122,750. Separate derivative line shows 2,500 shares disposed at $0.00 (filing gives no additional explanation).
• Plan/notes: Sales were effected under a prearranged Rule 10b5-1 trading plan dated Sept 17, 2025 (F1). Underlying option shares are fully vested (F4).
• Timeliness: Filing date and report date are both Feb 20, 2026 (timely filing).

Context

• This was a mixed transaction: an option exercise (acquisition) paired with open-market sales. The sales were executed under a pre-existing 10b5-1 plan, which is a commonly used mechanism for prearranged insider sales. The filing does not specify post-transaction beneficial ownership, so total shares owned after these transactions are not disclosed in the provided data.